17,250 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by Everence Capital Management Inc.

Everence Capital Management Inc. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,250 shares of the company’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Commonwealth Equity Services LLC lifted its holdings in shares of Elanco Animal Health by 11.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 34,942 shares of the company’s stock worth $504,000 after purchasing an additional 3,647 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Elanco Animal Health by 13.5% during the second quarter. TD Asset Management Inc now owns 379,342 shares of the company’s stock valued at $5,474,000 after acquiring an additional 45,203 shares during the period. Arizona State Retirement System grew its position in shares of Elanco Animal Health by 2.1% during the second quarter. Arizona State Retirement System now owns 138,324 shares of the company’s stock worth $1,996,000 after acquiring an additional 2,892 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Elanco Animal Health in the 2nd quarter valued at about $170,000. Finally, Choreo LLC acquired a new position in Elanco Animal Health during the 2nd quarter valued at about $620,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on ELAN. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target on the stock. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price target for the company. Barclays increased their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus cut their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.43.

Elanco Animal Health Trading Down 2.3 %

Shares of ELAN stock opened at $11.53 on Thursday. The stock has a 50-day simple moving average of $12.71 and a 200 day simple moving average of $13.55. The stock has a market capitalization of $5.70 billion, a P/E ratio of 28.83, a P/E/G ratio of 2.03 and a beta of 1.41. Elanco Animal Health Incorporated has a fifty-two week low of $11.28 and a fifty-two week high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the company posted $0.18 EPS. The business’s revenue was down 3.6% compared to the same quarter last year. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.